Relay Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone. It's my pleasure to introduce the Relay management team. Next to me, I have Sanjiv Patel, President and CEO; and Peter Rahmer, Chief Corporate Development Officer. Thank you for joining us.
Questions & Answers
To start here, you've reported data from your PI3K-alpha inhibitor as a doublet and triplet in breast cancer as well as in rare disease and vascular anomalies in particular, could you provide an update on the company's strategy and what you plan to accomplish over the next 12 to 24 months, including further data and update for Zovegalisib in that period?
Absolutely. So first of all, thank you for the invitation, and thank you for the grand venue that we're in today. It's been a busy time over the last year for our company, our mutant selective PI3K inhibitor, Zovega, has had multiple data that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
